Evidence map›Paper›PMID 22695328›Full record

ArticleKidney international2012

Mesenchymal stem cells derived from adipose tissue are not affected by renal disease.

Marieke Roemeling-van Rhijn, Marlies E J Reinders, Annelies de Klein, Hannie Douben, Sander S Korevaar, Fane K F Mensah, Frank J M F Dor, Jan N M IJzermans, Michiel G H Betjes, Carla C Baan and 2 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Kidney international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03321942 (The Biological Characteristics of Adipose Tissue-derived Mesenchymal Stem Cells and Its Role in the Treatment of Chronic Renal Failure), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03321942 naunknown statusnot on this mapstarted 2017, after this paper: background citation

The Biological Characteristics of Adipose Tissue-derived Mesenchymal Stem Cells and Its Role in the Treatment of Chronic Renal Failure

TypeinterventionalSponsorThe Affiliated Hospital of Xuzhou Medical UniversityRan2017 to 2018Enrolled100ConditionsMesenchymal Stem Cells, Chronic Kidney Diseases, Renal Interstitial FibrosisArmsTreatment group, Control group
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. A perspective on chronic kidney disease progression.American journal of physiology. Renal physiology · 2017
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Marieke Roemeling-van RhijnDepartment of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. m.vanrhijn@erasmusmc.nl
Marlies E J Reinders
Annelies de Klein
Hannie Douben
Sander S Korevaar
Fane K F Mensah
Frank J M F Dor
Jan N M IJzermans
Michiel G H Betjes
Carla C Baan
Willem Weimar
Martin J Hoogduijn
Erasmus MC · NLErasmus University Rotterdam · NLLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells are a potential therapeutic agent in renal disease and kidney transplantation. Autologous cell use in kidney transplantation is preferred to avoid anti-HLA reactivity; however, the influence of renal disease on mesenchymal stem cells is unknown. To investigate the feasibility of autologous cell therapy in patients with renal disease, we isolated these cells from subcutaneous adipose tissue of healthy controls and patients with renal disease and compared them phenotypically and functionally. The mesenchymal stem cells from both groups showed similar morphology and differentiation capacity, and were both over 90% positive for CD73, CD105, and CD166, and negative for CD31 and CD45. They demonstrated comparable population doubling times, rates of apoptosis, and were both capable of inhibiting allo-antigen- and anti-CD3/CD28-activated peripheral blood mononuclear cell proliferation. In response to immune activation they both increased the expression of pro-inflammatory and anti-inflammatory factors. These mesenchymal stem cells were genetically stable after extensive expansion and, importantly, were not affected by uremic serum. Thus, mesenchymal stem cells of patients with renal disease have similar characteristics and functionality as those from healthy controls. Hence, our results indicate the feasibility of their use in autologous cell therapy in patients with renal disease.

Indexed as

5'-NucleotidaseActivated-Leukocyte Cell Adhesion MoleculeAdipose TissueAdultAgedAntigens, CDApoptosisBiomarkersCase-Control StudiesCD28 AntigensCD3 ComplexCell Adhesion Molecules, NeuronalCell DifferentiationCell ProliferationCells, CulturedCell Separation5'-NucleotidaseActivated-Leukocyte Cell Adhesion MoleculeALCAM protein, humanAntigens, CDBiomarkersCD28 AntigensCD3 ComplexCell Adhesion Molecules, NeuronalEndoglinENG protein, humanFetal ProteinsGPI-Linked ProteinsInflammation MediatorsLeukocyte Common AntigensNT5E protein, humanPlatelet Endothelial Cell Adhesion Molecule-1PTPRC protein, humanReceptors, Cell Surface

Identifiers

PMID22695328
OpenAlexW2049737910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.